Drug Trial Radar · NCT07911748
A Study of MBS314 for Injection in Participants With Relapsed/Refractory Multiple Myeloma.
Last checked: Nov 19, 2026Latest source record: Nov 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
78
Planned (sponsor's estimate)
Start
Nov 2026
Primary completion
Dec 2027
Study completion Nov 2028
Sponsor
- Lead sponsor
- Beijing Mabworks Biotech Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Nov 3, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase I/II, multicenter, open-label, dose-escalation and dose-expansion study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and efficacy of MBS314, a novel asymmetric trivalent trispecific humanized antibody targeting GPRC5D, BCMA and CD3, administered by subcutaneous (SC) injection in participants with relapsed or refractory multiple myeloma. The investigational drug is MBS314 for Injection (high-concentration lyophilized formulation, 90 mg/vial, reconstituted to 90 mg/mL); this study is the first-in-human (FIH) study of this formulation. The study is divided into 2 parts: a dose escalation part (Phase I) and a dose expansion part (Phase II). In Phase I, eligible participants will be sequentially assigned to 1 of the 3 planned dose cohorts and receive MBS314 by SC injection using a step-up dosing (SUD) strategy, and dose escalation follows the Bayesian Optimal Interval (BOIN) design with a target toxicity rate of 33%. In Phase II, 1 to 3 dose groups will be selected based on Phase I results to further evaluate the efficacy of MBS314 at the recommended dose(s).
Conditions
- Multiple Myeloma
Interventions
MBS314 for InjectionDrug
Phase I: Eligible participants will be sequentially assigned to one of three dose groups under BOIN design (Dose Group 1: 3-step SUD \[0.5/3.0/15.0 mg\], target dose 90.0 mg; Dose Group 2 \[tentative\]: 3-step SUD \[1.5/9.0/45.0 mg\], target dose 135.0 mg; Dose Group 3 \[tentative\]: 3-step SUD \[2.5/15.0/90.0 mg\], target dose 180.0 mg). MBS314 is given subcutaneously (single injection volume ≤2.0 mL; injection sites ≥2 cm apart). Step-up dosing is used in Cycle 1: priming doses on C1D1, C1D4, C1D7 and target dose on C1D10. From Cycle 2 onwards, target dose is administered Q4W. Phase II: Based on Phase I findings, 1-3 dose groups will be selected for dose expansion (10-20 participants per group, total 10-60).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase I :Percentage of Participants with Adverse Events (AEs)Time frame: From Baseline up to 28 (+7) days after the last dose of MBS314]
- Phase I:Incidence of Dose Limiting Toxicities (DLTs)Time frame: From Baseline up to 4 weeks
- Phase I:Maximum Tolerated Dose (MTD) (if any) or Optimal Biological Dose (OBD) of MBS314Time frame: Up to approximately 7 months
- Phase I:Recommended Phase Ⅱ Dose (RP2D) of MBS314Time frame: Up to approximately 7 months
- Phase II:Efficacy: Overall Response Rate (ORR) as Assessed by the InvestigatorTime frame: Up to approximately 15 months
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.